AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 165 filers reported holding AKERO THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $944,000 | +317.7% | 18,665 | +284.8% | 0.00% | – |
Q2 2023 | $226,000 | +78.0% | 4,850 | +45.9% | 0.00% | – |
Q1 2023 | $127,000 | -56.5% | 3,325 | -37.4% | 0.00% | – |
Q4 2022 | $292,000 | +228.1% | 5,312 | +103.9% | 0.00% | – |
Q3 2022 | $89,000 | +304.5% | 2,605 | +9.9% | 0.00% | – |
Q2 2022 | $22,000 | -58.5% | 2,370 | -37.5% | 0.00% | – |
Q1 2022 | $53,000 | -67.1% | 3,793 | -50.2% | 0.00% | – |
Q4 2021 | $161,000 | +66.0% | 7,623 | +74.6% | 0.00% | – |
Q3 2021 | $97,000 | -2.0% | 4,365 | +9.9% | 0.00% | – |
Q2 2021 | $99,000 | +28.6% | 3,972 | +49.8% | 0.00% | – |
Q1 2021 | $77,000 | +60.4% | 2,652 | +44.8% | 0.00% | – |
Q4 2020 | $48,000 | +41.2% | 1,831 | +67.8% | 0.00% | – |
Q3 2020 | $34,000 | +25.9% | 1,091 | 0.0% | 0.00% | – |
Q2 2020 | $27,000 | +12.5% | 1,091 | -4.3% | 0.00% | – |
Q1 2020 | $24,000 | +41.2% | 1,140 | +53.2% | 0.00% | – |
Q4 2019 | $17,000 | +1600.0% | 744 | +1590.9% | 0.00% | – |
Q3 2019 | $1,000 | – | 44 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |